Octavio Alejandro Fuentes Méndez

Urólogo @INCMNSZ / Uro-Oncólogo @INCAN

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer

https://t.co/yb3G1t7bN2

Review synthesises international guidance on lutetium-177 PSMA radioligand therapy (177Lu-PSMA-RLT) in #ProstateCancer , focusing on metastatic castration-resistant disease. Major societies, including EAU, NCCN, ASCO, AUA/SUO, and CUA, endorse 177Lu-PSMA-617 after prior ARPI and taxane therapy, supported by VISION and TheraP trial data. Emerging evidence from PSMAfore is expanding use into earlier treatment settings.

Current recommendations emphasise PSMA-positive patient selection, standardised dosing, androgen deprivation therapy continuation, and multidisciplinary management.

@declangmurphy @DrMHofman @AzadOncology @RenuEapen @lawrentschuk @drMPerera

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists

[Maite Bourlon @BourlonMaite]

Starting today!!! #IPCS2026 & #APCCC2026

Check the wonderful agenda ✅
https://t.co/KyTD89ajSz in person and online📤

Great faculty @Silke_Gillessen @Ecastromarcos @DrYukselUrun @tompowles1 @EAntonarakis @oncodaily @OncoAlert @urotoday

[Eduardo Corona-Rodarte @CoronaRodarte]

El maestro fue alumno. El hábil fue torpe. El experto fue alguna vez ignorante. El campeón fue novato.

Somos procesos.

[Mohammed Shahait @MShahait]

New in @UrolOncol
Our review on “Etiology of Testosterone Deficiency After RP” highlights an underrecognized consequence of RP:
• ~1 in 3 men develop testosterone deficiency
• Likely due to venous disruption & ischemia
• Most recover within 12 months

➡️ Takeaway: Not all post-RP low libido, or delayed recovery is “expected”—testosterone matters

@faysal_a_yafi @Mo_Moukhtar
#prostatecancer #MensHealth
https://t.co/kSQLmBha3P

[Michael Hofman @DrMHofman]

6/ Watch the @gu_onc #PRIMARY2 episode now! https://t.co/Vfpy0xselp

[Michael Hofman @DrMHofman]

3/ Importantly, #PRIMARY2 also reduced the diagnosis of insignificant prostate cancer - helping move us toward a smarter diagnostic pathway with fewer unnecessary biopsies, less overdiagnosis, and more precise targeting for those who do need biopsy.

[Michael Hofman @DrMHofman]

2/ The key finding: adding PSMA PET/CT to current standard-of-care halved the number of prostate biopsies. Biopsy was avoided in 49% of men, without missing clinically significant prostate cancer.

[Michael Hofman @DrMHofman]

Proud moment and HUGE news from #EAU26: #PRIMARY2 shows PSMA PET/CT can safely halve prostate biopsies in men with equivocal MRI, avoiding biopsy in 49% without missing cancer. https://t.co/OOGooac59C

[UroToday.com @urotoday]

Extended vs limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk #ProstateCancer: 10 years of follow up - oncological outcomes from a randomized phase 3 trial. Presented by Matheus Ruggeri. #EAU26 written coverage by @zklaassen_md > https://t.co/hsySWX1P9K @Uroweb

[Julian Chavarriaga @chavarriagaj]

#EAU26 Intensification strategies in HR-NMIBC
Dr. Xylinas reviews CREST, ALBAN, POTOMAC

🔹 ALBAN ❌ atezolizumab + BCG → no EFS benefit
🔹 CREST ✅ sasanlimab + BCG → improved EFS (HR 0.68)
🔹 POTOMAC ✅ durvalumab + BCG → improved DFS (HR 0.68)

🎯 Benefit mainly driven by ↓ high-grade recurrence
🚩BCG maintenance for 2y remains critical
@uroweb @urotoday

[Shankar Siva @_ShankarSiva]

📣@ChapinMD presents best systemic therapy trial +/- prostatectomy n=120 randomised phase II trial in #prostatecancer. No observed benefit for prostatectomy 🔪🩸. Ongoing recruitment for SWOG-1802, pls support this important clinical trial 👏🏽#pcsm #EAU26

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

[68Ga]PSMA-11 PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX)

https://t.co/Ytf1goIUkH

This prospective trial compared [68Ga]PSMA-11 PET/CT and mpMRI in men with suspected #ProstateCancer after a prior negative biopsy. Among 130 patients, PET/CT demonstrated higher diagnostic accuracy for clinically significant disease than mpMRI. PSA density, PRIMARY score, SUVratio, and PI-RADS predicted significant cancer.

Investigators developed the PRIMER nomogram, which showed strong performance (AUC 0.896) for predicting clinically significant prostate cancer before repeat biopsy.

Egesta Lopci,
@FasuloVittorio
@RobPeschechera
@GLughezzani

@OncoAlert 🚨
@silkegillessen
@AOmlin
@weoncologists

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

PEACE-2 Presented at #GU26

https://t.co/9lYVA4QnHJ

PEACE-2 evaluated whether adding upfront cabazitaxel to long-term ADT and prostate radiotherapy improves outcomes in very high-risk localized #ProstateCancer .

In this 2×2 factorial phase III trial of 761 patients, no interaction was seen with pelvic radiotherapy☢️, and cabazitaxel did NOT🚫improve clinical progression-free survival (HR 1.11), with similar overall survival across arms after a median 85 months. Toxicity was higher with cabazitaxel, and prostate cancer–related deaths were rare.

Karim Fizazi
@PaulSargos
Igor Latorzeff @AFUrologie
@EnriqueGallar12
@PBlanchardMD

@OncoAlert 🚨
@silkegillessen
@AOmlin
@weoncologists

[Mirrors of Medicine @mirrorsmed]

Phase 3 LITESPARK-022 trial Presented at #GU26

https://t.co/KYZyUFI49v

The addition of belzutifan to one year of pembrolizumab after nephrectomy in patients with high-risk clear cell RCC significantly improved disease-free survival compared with pembrolizumab alone, lowering📉the risk of recurrence or death by 28% (HR 0.72).

At 24 months, DFS rates were 80.7% with the combination versus 73.7% with pembrolizumab🧪

Although grade ≥3 adverse events were more frequent—including anemia, hypoxia, and elevated liver enzymes—they were generally manageable with dose adjustments and supportive care.

Source Linked: ASCO Daily News

@DrChoueiri
@motzermd
@DrIacovelli
@DrYukselUrun
@elena_verzoni
@tompowles1
@OncoAlert 🚨

[Elena Castro @Ecastromarcos]

Just out in @TheLancet: an overview on current approaches to diagnosis and management of prostate cancer.
https://t.co/AhomCOFkZg

[Tom Powles @tompowles1]

Perioperative Enfortumab Vedotin and pembrolizumab beats neoadjuvant chemotherapy & cystectomy in muscle invasive bladder cancer. We’re moving towards a bladder surgery sparing strategies using EVP. This is another step towards curing bladder cancer https://t.co/UEV0JiM1iC

[Departamento de Urologia INCMNSZ @INCMNSZ_Uro]

Reunión de Egresados del Departamento de Urología del @incmnszmx durante el reciente Congreso 2025 de la @smumexico

Una gran oportunidad para convivir con excelentes amigos y grandes especialistas.

[Octavio Alejandro Fuentes Méndez @Fuentes1702]

#SMU #CongresoNacionalUrologia2025

[Shankar Siva @_ShankarSiva]

🚫 In >2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms).
🔹 PC-specific survival 98%
🔹 Slight ↓ in biochemical failure with WPRT
🔹 More grade 2 GI adverse events
⁉️how to reconcile with POP-RT trial in PSMA era? Lower risk cohort? #ASTRO25 #RadOnc

[Maite Bourlon @BourlonMaite]

Recaída bioquímica #cancerprostata @RodRogSan presentando en @SMEOMX 🔆🤩👨🏻‍⚕️🦀🌍

🔴RT de salvamento infrautilizada
🟢Q vamos irradiar: lecho, gl!
🟠Tiempo de tx hormonal: 6 vs 24 m
🔵 EMBARK study: ADT vs Enza vs Enza + ADT